Prevalence and seroprevalence of low-risk human papillomavirus in Korean women

Journal of Korean Medical Science

Volumn 27, Issue 8, 2012, Pages 922-928

  Kim, Min A ^a   Oh, Jin Kyoung ^b   Kim, Bo Wook ^a   Chay, Doobyung ^c   Park, Dong Choon ^d   Kim, Seok Mo ^e   Kang, Eun Suk ^f   Kim, Jae Hoon ^a   Cho, Chi Heum ^g   Shin, Hai Rim ^h   Seo, Kyung ^a  

^a Yonsei University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Chonnam National University Medical School   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Keimyung University School of Medicine   (South Korea)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Low risk human papillomavirus; Prevalence; Seroprevalence

Indexed keywords

ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CHILD; EPIDEMIOLOGY; FEMALE; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOLOGY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PREVALENCE; RISK; RISK FACTOR; SEXUAL BEHAVIOR; SOUTH KOREA;

ADOLESCENT; ADULT; ANTIBODIES; CHILD; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; MIDDLE AGED; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; REPUBLIC OF KOREA; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; YOUNG ADULT;

EID: 84866516970     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.8.922     Document Type: Article

References (32)

1. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005; 37: S3-9.
2. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24 Suppl 3: S3/35-41.
3. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003: 3-13.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
5. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995; 33: 2058-63.
6. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10: 122-63.
7. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006; 61: S3-14.
8. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13: 110-6.
9. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006; 194: 1044-57.
10. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, Kong HJ, Rha SH, Jung SI, Kim JI, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004; 190: 468-76.
11. Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, Chichareon S, Kaenploy V, Ashley R, Meijer CJ, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003; 187: 1246-56.
12. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-9.
13. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94: 1406-14.
14. Clifford GM, Shin HR, Oh JK, Waterboer T, Ju YH, Vaccarella S, Quint W, Pawlita M, Franceschi S. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007; 16: 1874-9.
15. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003; 103: 413-21.
16. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10: 108-15.
17. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12: 959-69.
18. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-9.
19. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92: 464-74.
20. Lee YH, Choe JY, Park SH, Park YW, Lee SS, Kang YM, Nam EJ, Park W, Kwon SR, Bae SC, et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci 2010; 25: 1431-7.
21. Hankins C, Coutlee F, Lapointe N, Simard P, Tran T, Samson J, Hum L. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. CMAJ 1999; 160: 185-91.
22. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24: S1-15.
23. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, Ning L, Killeen J, Kamemoto L, Hernandez BY. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008; 68: 8813-24.
24. Skjeldestad FE, Mehta V, Sings HL, Ovreness T, Turpin J, Su L, Boerckel P, Roberts C, Bryan J, Jansen KU, et al. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008; 87: 81-8.
25. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009; 200: 1059-67.
26. Newall AT, Brotherton JM, Quinn HE, McIntyre PB, Backhouse J, Gilbert L, Esser MT, Erick J, Bryan J, Formica N, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008; 46: 1647-55.
27. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174: 927-36.
28. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373: 1949-57.
29. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001; 8: 209-20.
30. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24: S16-22.
31. Hariri S, Dunne EF, Sternberg M, Unger ER, Meadows KS, Karem KL, Markowitz LE. Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health And Nutrition Examination Survey, 1991-1994. Sex Transm Dis 2008; 35: 298-303.
32. Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, Nam JH, Ahn WS, Choi HS, Ng T, et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J Korean Med Sci 2010; 25: 1197-204.